CD16 transfection into YT cells confers an increase in lytic power against selected tumor targets.

YT/CD16⁺ cells showed increased cytotoxicity toward B-cell lines (Raji, Daudi, RPMI 8226, Karpas 707, ARH 77, and LP-1) and myeloid cell lines (NB-4 and U937). Data are mean ± SD (vertical bars) results from at least 3 independent experiments.